annb0t
Top 20
MELBOURNE, Australia, July 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 June 2023 (Q2 2023). All figures are in AUD$ unless otherwise stated[1] and provided on an unaudited basis. (PRNewsfoto/Telix Pharmaceuticals Limited)
Summary
Total revenue up 21% quarter-on-quarter to $120.7M driven by global product sales Positive operating cas...
>>> Read more: Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow
Summary
Total revenue up 21% quarter-on-quarter to $120.7M driven by global product sales Positive operating cas...
>>> Read more: Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow